R.A. (Rudolf) de Boer

Field/Discipline

• Cardiac & Cardiovascular Systems
• Medicine, Research & Experimental
• Genetics & Heredity

Expertise

Other positions

• Dutch Society of Cardiology, President-elect (2021-2023)
• ESC, Heart Failure Association (HFA), Board member Basic Section (2014-2020)
• Fellow of the European Society of Cardiology (FESC, 2010 - onwards)
• ESC Council on Cardio-Oncology, Liaison Officer (2020-2022)
• Project leader, research project heart failure and diabetes, sponsored by Novo Nordisk
• Project leader, research project heart failure and diabetes, sponsored by Novo Nordisk
• Project leader, research project heart failure, sponsored by Cardior GmbH
• Project leader, research project heart failure, sponsored by Ionis Pharmaceuticals, Inc.
• Project leader, research project heart failure, sponsored by Boehringer Ingelheim
• Project leader, research project heart failure, sponsored by Roche Diagnostics
• Project leader, grant European Research Council (ERC CoG 818715, SECRETE-HF)
• Project leader, grant Netherlands Heart Foundation, CVON DOUBLE DOSE, grant 2020B005
• Project leader, grant Netherlands Heart Foundation, CVON SHE-PREDICTS-HF, grant 2017-21
• Project leader, grant Netherlands Heart Foundation, CVON RED-CVD, grant 2017-11
• PI, grant Netherlands Heart Foundation, CVON PREDICT2, grant 2018-30
• PI, grant from the leDucq Foundation (Cure PhosphoLambaN induced Cardiomyopathy (Cure-PLaN)
• Speaker fee, Bayer AG
• Speaker fee, BIAL
• Speaker fee, Novartis Pharma
• Member Executive Committee of the Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure (DELIVER) clinical trial
• Co-PIof the Hemodynamic Monitoring with the CardioMEMS PA sensor and Quality of Life in Patients with Chronic Heart Failure (MONITOR-HF) study
• PI CARDIATEAM (Cardiomyopathy in type 2 diabetes mellitus), IMI MI2 - agreement number 821508
• Member working group guideline Heart Failure, Dutch GP Society (NHG)